This course will highlight Biology Science from the following abstracts:
- Deletion of the Tumor Suppressor Gene PTEN in ETS-Fusion Positive Prostate Cancer Identifies Patients with High Risk Pathology that may Benefit from Adjuvant Radiation
- Molecular Biomarkers for Chemoradiotherapy Response in Unresectable Limited Stage Small Cell Lung Cancer
- Pre-Treatment Circulating Tumor Human Papillomavirus (HPV) DNA and Recurrence Risk in HPV Associated Malignancy: Oropharyngeal, Anal Canal, and Cervical Cancer
- Mitigation of late cardiac toxicity following radiotherapy through abrogation of cGAS/STING-dependent interferon (IFN)
- Specific Taxa of the Intestinal Microbiome Mitigate the Radiation-Induced Gastrointestinal Syndrome
The course is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, learners should be able to do the following:
- Articulate how the described advances could impact your clinical practice in the coming years.
- Recognize the importance of supporting basic science to broaden the uses of radiation.
Randall Kimple, MD, PhD is employed by University of Wisconsin and receives compensation/remuneration/funding from Galera therapeutics.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
- 0.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.50 Certificate of AttendanceThis activity was designated for 0.50 AMA PRA Category 1 Credit™.